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Achalasia is an esophageal motility disorder of unknown cause that manifests as symptoms of difﬁculty in swallowing, with pooling of food and se-
cretions in the lower esophagus. Endoscopic treatment for achalasia is directed at disrupting or weakening the lower esophageal sphincter (LES). As
botulinum toxin (botox) is a potent inhibitor of acetylcholine release from nerve endings, it counteracts the unopposed LES contraction that is mediated
by cholinergic nerves, thereby lowering LES pressure. In general, a total dose of 100 IU is endoscopically injected in the LES using a sclerotherapy needle,
in four gifts, one in each quadrant. The response rates at 1 month following administration are 78% on average (range, 63–90%). By 6 months, the clinical
response rate drops to 58% (range, 25–78%); and by 12 months, this further drops to 49% (range, 15–64%). The predictors of response to botulinum toxin
injection (BTI) include age greater than 50 years, and the presence of vigorous achalasia, deﬁned by the ﬁnding of esophageal contractile waves, with
amplitudes in excess of 40 mmHg. Meanwhile, the duration of illness, baseline radiographic features, initial symptom severity, and sex have not been
shown to be predictive of response. Compared to both pneumatic dilation and myotomy, BTI has clearly shown to have been at a disadvantage with
respect to therapeutic efﬁcacy. However, BTI has several advantagesdsuch as ease of technique, safety, ease of return to work, and higher success rate in
vigorous achalasiadcompared with pneumatic dilation and surgical myotomy. Botulinum toxin should be preferentially reserved for patients with
signiﬁcant comorbidity, and is not adequate for conventional treatment with laparoscopic Heller’s myotomy or pneumatic dilation, or for patients who are
on a waiting list for surgery or who are refusing other forms of treatment.
Copyright  2014, Society of Gastrointestinal Intervention. Published by Elsevier.
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Achalasia is an esophageal motility disorder of unknown cause
that manifests as symptoms of difﬁculty in swallowing, with
pooling of food and secretions in the lower esophagus. The onset of
symptoms is often insidious, and usually occurs between the ages
of 25 years and 60 years. An increasing incidence with age has been
observed, with an equal male-to-female sex distribution;moreover,
symptoms gradually progress over a period of years.1
The condition is characterized by degeneration of ganglion cells,
predominantly the inhibitory neurons in the myenteric plexus of
the lower esophageal sphincter (LES). This leads to a rise in the basal
tone of the sphincter, loss of peristalsis in the distal esophagus, and a
lack of coordinated LES relaxation, in response to swallowing.
The usual treatment for achalasiadballoon dilation or myotomy
of the LESdis aimed at lowering the resting pressure of the
sphincter.2 In the past two decades, intrasphincteric injection of
botulinum toxin has emerged as an alternative to pneumatic dila-
tion.3,4 The hypothesis was based on the concept that the net
sphincter tone in the gut results from a balance between excitatory
inﬂuences (acetylcholine and substance P) and inhibitory in-
ﬂuences (vasoactive intestinal peptide and nitric oxide).5 InDigestive Disease Center, Konkuk University School of Medicine, Seoul, Korea
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the inhibitory nerves,6–8 resulting in a hypertonic LES that fails to
relax. By blocking the release of acetylcholine, locally injected
botulinum toxin may restore the LES to a more normal resting tone.
It is a safe procedure, being associated with few side effects or
complications.9
In the early stages of idiopathic achalasia, both barium swallow
and endoscopy can be normal. In more advanced cases, endoscopy
may show a dilated esophagus with retained food, and some
resistance at the gastroesophageal junction (Fig. 1A and B). Barium
swallow typically reveals a “bird-beak” image at the junction, with
a dilated esophageal body, and an air–ﬂuid level, in the absence of
an intragastric air bubble (Fig. 1C and D). Endoscopy is diagnostic in
one-third of the patients, whereas barium swallow is diagnostic in
two-thirds of the patients. Diagnostic certainty is provided by
manometry in 90% of the patients and requires two pathognomonic
abnormalities: aperistalsis of the esophageal body and an incom-
plete relaxation of the LES after deglutition.10 However, despite the
absence of peristalsis, there can still be substantial pressurization
within the esophagus. This review discusses the endoscopic botu-
linum toxin injection (BTI) method, effects of intervention, possible
complications, and beneﬁt and limitation.vier. Open access under CC BY-NC-ND license.
Fig. 1. Endoscopy showing (A) a dilated esophagus with retained food and (B) tightness, with some resistance at the gastroesophageal junction (GEJ). Barium swallow, showing
(C) a “bird-beak” image at the GEJ, with (D) a dilated esophageal body and an air–ﬂuid level.
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As botulinum toxin (botox) is a potent inhibitor of acetylcholine
release from nerve endings, it counteracts the unopposed LES
contraction mediated by cholinergic nerves, thereby lowering LES
pressure. In general, a total dose of 100 IU is endoscopically injected
in the LES using a sclerotherapy needle, in four injections, one in
each quadrant.
There are only general guidelines concerning the technique of
botox injection. An injection needle is used to make the injection at
the squamocolumnar junction, of up to 1 cm proximal. An attempt
is made to equally space the injections in a circumferential manner,
and at the same level (Fig. 2). Attention should be paid to main-
taining a perpendicular relationship to the esophageal wall, and
avoiding submucosal injection (a visible bleb) or injection outside
the esophageal wall. The assistant can usually give feedback
regarding the degree of resistance to injection, which should be
consistent. Other variations, such as injecting in retroﬂexion, using
endoscopic ultrasound, or using different types of botulinum toxin,Fig. 2. Botox injection method (A) An injection needle is used to make injections at (B, C) the
four to ﬁve equal volume aliquots, to (D) equally space the injections in a circumferential mhave not gained in popularity.11 Antibiotics are not usually given,
and patients can be discharged immediately, if stable. LES pressure
decreases on average by 50% a week after the initial injection, and
esophageal emptying improves.12 Increasing the dose to 200 IU
(botox) does not improve the rate of success, whereas repeating a
100-IU injection after 1 month may improve its efﬁcacy.13
Effects of intervention
BTI was ﬁrst introduced as a viable treatment for achalasia
nearly two decades ago. In their report, Pasricha et al4 demon-
strated symptomatic improvement in 82% of the patients after
BTI, compared with 10% of those who received placebo. This trial
was followed by a prospective, long-term follow-up study,
which showed that two-thirds of patients who received BTI have
an improved symptom response, at a mean follow-up of 2.4
years.14
In general, a total dose of 100 IU is endoscopically injected in the
LES, using a sclerotherapy needle. A large multicenter studysquamocolumnar junction, or up to 1 cm proximally. Then, 100 IU in total is injected in
anner, and at the same level.
Chan Sup Shim / Temporary cecostomy in neutropenic colitis 21reported that a dose of 100 IU, followed 1 month later by a second
100-IU injection in responders, was more efﬁcacious than either 50
IU or 200 IU administered in a single dose.13 At a mean follow-up of
12 months, relapse was seen in 19% of patients treated with the
double injections of 100 IU, compared with 47% and 43% of the pa-
tients receiving 50 IU and 200 IU doses, respectively. Increasing the
dose to 200 IU does not improve the rate of success, whereas
repeating a 100-IU injection after 1monthmay improve its efﬁcacy.9
Fifteen prospective studies in the literature have examined the
efﬁcacy of botulinum toxin. The response rates at 1 month
following administration average 82% (range, 69–90%). By 6
months, the clinical response rate drops to 57% (range, 33–77%),
and by 12 months to 48% (range, 15–76%; Table 1).3,4,9,11,14–25 It is
apparent that with repeated injections, the response rates reported
are similar or lower to that achieved with the initial injection. The
diminishing effect may be attributable to the development of
protective antibodies against the botulinum toxin mole-
cule.13,14,25,26 The use of a different serotype of botulinum toxinmay
be a way of prolonging response rates, although this approach re-
mains to be proven.Predictors for long-term success of BTI
Interestingly, the therapeutic response differs between the
manometric subtypesdpanesophageal pressurization is found to
be a predictor of a positive treatment response, whereas spastic
achalasia is associated with a negative treatment response.
Pandolﬁno and colleagues27,28 proposed classiﬁcations into
three different subtypes: type I, classic achalasia with no evidence
of pressurization; type II, panesophageal pressurization; and type
III, vigorous achalasia, or two or more spastic contractions of the
distal esophageal segment. Older age, moderate LES pressure, and
“vigorous” achalasia (type III) have been identiﬁed by some re-
searchers as factors predicting a favorable response to botox
injection.14
Predictors of response to BTI include age greater than 50 years
and the presence of vigorous achalasia, deﬁned by the ﬁnding of
esophageal contractile waves, with amplitudes in excess of
40 mmHg.14 The duration of illness, baseline radiographic features,
initial symptom severity, and sex have not been shown to be pre-
dictive of response.
Patients older than 50 years of age had nearly double the
response rate, compared with younger patients (82% vs. 43%;
P ¼ 0.03). This difference in response rates caused by age was





6 mo (%) 12 mo (%)
Pasricha et al 19943 21 90 67
Pasricha et al 19954 10 90 50
Cuillière et al 19979 55 69 60
Pasricha et al 199614 31 90 55
Fishman et al 199615 60 70 46
Kozarek et al 199716 36 58
Gordon and Eaker 199717 16 75 43
Annese et al 199818 57 88
Muehldorfer et al 199919 12 75
Prakash et al 199920 42 62 41
Kolbasnik et al 199921 30 57 39
Mikaeli et al 200122 20 15
Bansal et al 200323 18 94 33
Zaninotto et al 200424 17 76
Zaninotto et al 200425 40 77 60
Total (range of mean) 465 82 (69–90) 57 (33–77) 48 (15–76)
BTI, botulinum toxin injection.P ¼ 0.04). However, in the presence of vigorous achalasia, the
response to BTI was uniformly favorable regardless of age.14
Because local BTI is less invasive than pneumatic dilation or
surgical myotomy, it may be the procedure of choice for the treat-
ment of achalasia. However, the long-term results are less favorable
than those of dilation or myotomy.20,26 One study analyzed the
outcome in 25 patientswith achalasia, after amedian of 2.5 years, in
order to deﬁne the parameters that predict a good long-term
outcome.29 In this study,29 patients with a lower esophageal
sphincter pressure (LESP) prior to treatmentwere particularly likely
to beneﬁt from the BTI. In patients who responded manometrically
to the treatment, the average LESP reductionwas 30%. The degree of
pressure reduction was independent of the initial LESP; further-
more, there was no difference between long- and short-term re-
sponders with respect to initial pressure reduction.29
In all studies, long-term responders have been found to be
signiﬁcantly older than short-term responders.4,14,15,30,31 Botuli-
num toxin relieves LESP through reduction of the excitatory
cholinergic innervation of the sphincter. It leads to an irreversible
decline of end-phase potentials. The recovery of neurotransmission
and subsequent muscle activity requires the sprouting of new
nerve endings, and formation of new synaptic contacts to the
adjacent muscle ﬁbers.32,33 It is highly possible that in elderly pa-
tients, the capability of this regenerative process is reduced, thus
leading to a longer-lasting response.
Predictors for the long-term success of botulinum toxin are the
presence of vigorous achalasia, an LESP not exceeding the upper
normal limit by more than 50% in patients without vigorous
achalasia, age greater than 55 years, and mode of treatment (repeat
injection after 4 weeks).29
Possible complications
BTI for achalasia has an excellent safety proﬁle. Transient chest
pain is usually mild and has been reported in approximately 20% of
patients. Signiﬁcant heartburn is reported in approximately 5–10%
of patients.11 Isolated case reports of potential adverse events
have included heart block, urinary retention, and pneumothorax.
Case reports have noted mediastinitis, gastroparesis, and fatal
arrhythmia; however, thesemay relate to a suboptimal technique.34
Concerns regarding the potential for systemic neuromuscular
paralysis have not been realized in gastrointestinal or neurologic
applications, because the doses used in practice are 20–30-fold
lower than the lethal doses reported in previous studies.11
Beneﬁt and limitation
Most studies show that BTI is inferior, in terms of therapeutic
efﬁcacy, to both pneumatic dilation and myotomy.35,36 A recent
study demonstrated that pneumatic dilation may remain an
effective treatment if administered in an on-demand fashion.37 A
total of 150 patients were treated with pneumatic dilation until
remission was achieved, which occurred in 90% of the patients.
Patients were then dilated only if their symptoms returned, and the
probability of the patients achieving remission at 5 years and 10
years was 97% and 93%, respectively.37 Previous studies have sug-
gested that the remission rates for open Heller myotomy deterio-
rate over time.38,39 In one study, 95% success rates at 1 year fell to
77% at 5 years, 68% at 10 years, and 67% at 20 years.39 Short-term
data with laparoscopic Heller myotomy demonstrated excellent
results, with 98% of patients reporting symptomatic improvement
at 5.3 years.40 But the most compelling aspects of BTI for achalasia
are the ease of technique, and the low rate as well as the mild
degree of complications. It is for these reasons that botulinum in-
jection is commonly used in most centers worldwide. Indeed, one
Gastrointestinal Intervention 2014 3(1), 19–2322American survey found that BTI is themost common initial therapy,
despite its known inferior efﬁcacy.41
BTI has also been used as second-line salvage therapy, following
unsuccessful pneumatic dilation and surgical myotomy.31 Addi-
tionally, BTI prior to pneumatic dilation has been shown to have
beneﬁts.42 However, after BTI, there is an increased risk for pneu-
matic dilation perforation.43 One study showed that having prior
endoscopic treatment was more strongly associated with intra-
operative complications, especially esophageal perforation, and
persistent and recurrent symptoms requiring additional therapy,
after myotomy. However, other studies showed no difference in
intraoperative complications, degree of surgical difﬁculty, or
symptom improvement with prior endoscopic treatment.44 Botu-
linum toxin should be preferentially reserved for patients with
signiﬁcant comorbidity, and is not adequate for conventional
treatment with laparoscopic Heller’s myotomy or pneumatic dila-
tion, or for patients who are on a waiting list for surgery or who are
refusing other forms of treatment.
Studies comparing the cost-effectiveness of botulinum toxin,
pneumatic dilation, and surgical myotomy are rare. The cost of
treatment of botulinum toxin and pneumatic dilation are less than
that of surgical myotomy. Studies comparing the cost-effectiveness
of pneumatic dilation and Heller myotomy have in the past favored
dilation; however, the laparoscopic surgical approach has
decreased the length of hospitalization as well as additional sur-
gical costs.45 This fact, in combination with long-term pneumatic
dilation data suggesting a less than 40% remission rate, will likely
shift the cost analysis in favor of laparoscopic Heller myotomy.
The selection of pneumatic dilation or surgery as primary
therapy is still debated. Although surgery is more effective at
achieving a durable response, recurrent dysphagia occurs in a sig-
niﬁcant proportion of surgical patients. By contrast, pneumatic
dilation commonly requires repeated dilations, to sustain remis-
sion. Currently, the choice of therapy remains an individualized
decision that weighs factors that include available expertise, the
patient’s acceptance of possible risks, and factors such as age and
comorbidities.
Other current management and treatment options
The two most commonly used endoscopic interventions are
large balloon pneumatic dilation, and BTI. These interventions have
been extensively scrutinized, and compared with each other, as
well as with surgical disruption (myotomy) of the LES. Pneumatic
dilation is generally more effective in improving dysphagia in
achalasia than BTI,35,36 with the latter reserved for debilitated older
people. Per oral endoscopic myotomy is a newer endoscopic mo-
dality that will likely change the treatment paradigm for achalasia.
It arose from the ﬁeld of natural oriﬁce transluminal endoscopic
surgery and represents a scarless endoscopic approach to Heller
myotomy, with high short-term rates of success.46–48
Patients often receive therapy for achalasia that is not as well
validated, as the three traditional options of pneumatic dilation,
BTI, and myotomy. A retrospective analysis of a large achalasia
treatment cohort identiﬁed patients receiving nontraditional
endoscopic therapies, such as Savary dilation (20%), Maloney dila-
tion (10%), and small caliber balloon dilation, similar to that used
for esophageal strictures (4%).41 Although small caliber balloon
dilation (<30 mm) is generally ineffective by itself, it has been re-
ported that double small balloon dilation is more effective than
using a single balloon with 30 mm or larger diameter.49
There is also a recent single-center study reporting success with
novel endoscopic approaches; these results require further vali-
dation. Achalasia has been treated successfully using specially
designed covered metallic stents (usually 30 mm); however, thedata are limited, and there are no existing guidelines as to the
duration of stent placement.50
After BTI, patients with achalasia should be monitored on a
regular basis, to survey possible complications, such as a massive
dilated and sigmoid-shaped esophagus, and esophageal carcinoma.
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